The blockbuster medications could open a new frontier for the pharma giants. ...

ab 23 September 2025 Global Research Global Pharmaceuticals Framing Global GLP-1 forecasts to 2030 UBS forecast $130bn GLP-1 sales in 2030 Over the last 12 months, the outlook for the GLP-1 market for both obesity and type-2 diabetes (T2D) has weakened driven by the disruption from compounded product in the US market and from weaker than expected data from next generation assets (CagriSema and orforglipron). This has seen UBS 2030 global forecasts cut from > $150bn to $130bn, which assumes c.$80bn sales for ...

Core Insights - Eli Lilly has shown strong performance in the GLP-1 market, with significant commercial success from its products, particularly tirzepatide [1][10] - The company is on the verge of launching an oral GLP-1 medication, orforglipron, which has demonstrated superior efficacy in clinical trials compared to existing treatments [7][8] - Financial results indicate robust growth, with a 38% year-over-year revenue increase in Q2, reaching $15.6 billion, and a 61% rise in adjusted net earnings per share to $6.31 [10] Group 1: Product Development - Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, is generating billions in sales but is administered via injection, which has drawbacks compared to oral medications [3][4] - The company is developing orforglipron, which has shown a 1.9% average blood-sugar reduction and 8.2% weight loss in trials, outperforming Novo Nordisk's Rybelsus [7][8] - If orforglipron receives regulatory approval by year-end, it could significantly boost Eli Lilly's stock value [8][9] Group 2: Financial Performance - Eli Lilly's revenue and earnings growth outpace industry averages, with a forward P/E ratio of 24.7 compared to the healthcare industry's 16.5 [10][11] - Analysts project orforglipron could generate $12.7 billion in revenue by 2030, while tirzepatide is expected to reach nearly $62 billion in revenue by the same year [12][13] - The company has additional products in the pipeline, such as Kisunla for Alzheimer's and Ebglyss for eczema, which could also contribute to future growth [14] Group 3: Market Outlook - Eli Lilly's strong clinical data and market position suggest continued growth in the GLP-1 sector, with expectations for market-beating returns over the next five years [15]

Core Viewpoint - Eli Lilly has terminated a Phase 2b obesity trial for bimagrumab, which was intended to evaluate its efficacy both as a monotherapy and in combination with its main GLP-1/GIP drug, tirzepatide, before any participants were recruited [4][6]. Summary by Sections Trial Termination - The trial was initially planned to recruit 180 adults with obesity or overweight and type 2 diabetes, but was halted due to strategic business reasons [4]. - The status of the trial changed from "not yet recruiting" to "withdrawn," indicating a significant shift in the company's research strategy [6]. Ongoing Research - Despite the termination of the trial, bimagrumab is still being studied in another ongoing Phase 2 trial, which evaluates its efficacy alone or in combination with tirzepatide in the obese population, with results expected in 2026 [6]. Comparative Study Results - A related Phase 2 study presented at the American Diabetes Association meeting showed that patients receiving a combination of bimagrumab and semaglutide (Novo Nordisk's GLP-1 drug) had a significantly higher percentage of fat loss compared to those on semaglutide alone, with over 90% of weight loss in the combination group coming from fat [6].

Market Overview - Wall Street is on track to end the week higher, with the Dow up approximately 360 points, S&P 500 up about 0.6%, and NASDAQ up about 0.4% [2][3] - The Dow is up 0.8% for the day, while the NASDAQ is down about 0.67% for the week, marking the worst performance since August 1st [3][4] - The 10-year Treasury yield has increased by one basis point, indicating a trend of rising yields since Wednesday [5] Inflation and Federal Reserve Insights - The core Personal Consumption Expenditures (PCE) index for August is reported at 2.9%, consistent with July's figures, suggesting inflation is stable but not accelerating [11][12] - Federal Reserve officials express concerns about persistent inflation, with some suggesting that productivity gains from AI could mitigate inflationary pressures [13][14] - The next jobs report is anticipated to be crucial for the Fed's decision-making regarding interest rates, especially if it indicates a soft job market [14][16] Tariff Implications - President Trump's new tariff threats, including a 50% duty on certain pharmaceuticals and furniture, are causing concern in the affected industries, particularly in the furniture sector [17][18] - Companies like Wayfair and RH are adapting by diversifying their supply chains away from China, while pharmaceutical companies with U.S. manufacturing facilities are less affected by the tariffs [19][20] - The impact of these tariffs on inflation and economic growth is expected to vary by industry, with some sectors facing more significant challenges than others [22][23] Digital Asset Treasuries - Over 180 public companies have added Bitcoin to their balance sheets, indicating a growing trend in digital asset treasuries [74] - Breer Holdings is rebranding as Soulmate, focusing on a Solana-based digital asset treasury, highlighting the shift towards blockchain technologies that can handle high transaction volumes [75][87] - The emergence of digital asset treasuries is seen as a response to previous regulatory challenges and market inefficiencies, with a focus on building actual infrastructure to support these assets [91][92] Weight Loss Drug Market - The GLP-1 weight loss drug market is projected to potentially reach $100 billion annually within the next decade, driven by innovations and expanded indications beyond obesity [106][108] - Current injectable GLP-1 drugs show weight loss efficacy between 12% to 20%, with oral formulations expected to be slightly less effective [110][111] - Eli Lilly and Novo Nordisk dominate the market, but Amgen is also making strides with late-stage trials for its weight loss drug [105][116]

Hours after President Donald Trump imposed 100% tariffs on pharmaceuticals with exemptions for companies building manufacturing plants in the U.S., Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN) announced their latest investments in their home country. Lilly announced the opening of its ...

Core Insights - Eli Lilly and Company (LLY) received marketing authorization from the European Commission for Kisunla (donanemab) to treat early symptomatic Alzheimer's disease (AD) [1][7] - Kisunla is approved for adults with mild cognitive impairment (MCI) and mild dementia stage of AD with confirmed amyloid pathology [1][9] - The approval is supported by data from two late-stage studies, TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6, demonstrating significant slowing of cognitive and functional decline [2][9] Company Performance - Year to date, Eli Lilly's shares have declined by 7.4%, while the industry has seen a decrease of only 0.5% [4] Market Context - Kisunla is part of a competitive landscape in the AD treatment space, alongside Biogen/Eisai's Leqembi, which also targets early symptomatic AD [8][9] - Both drugs aim to reduce amyloid beta (Aβ) plaque accumulation, a key factor in cognitive decline associated with AD [9][10] - Kisunla has shown rapid uptake, recording sales of $70.1 million in the first half of 2025 [10]

Core Insights - Eli Lilly and Company is recognized as one of the top AI stocks to buy according to Goldman Sachs [1] - Wells Fargo has reiterated a Buy rating on Eli Lilly, maintaining a price target of $1,100 [1][3] Investment and Expansion - Eli Lilly plans to invest $5 billion in a new manufacturing facility in Virginia dedicated to cancer drugs, which will be the company's first fully integrated active pharmaceutical facility for bioconjugates and monoclonal antibodies [2] - This investment is part of Eli Lilly's broader commitment of $50 billion in U.S. capital expansion since 2020 [2] - The new facility is expected to create approximately 650 high-paying jobs and 1,800 construction jobs, positively impacting the local economy [3] Product Development and Clinical Trials - Eli Lilly's GIP/HLP-1 dual receptor agonist, Mounjaro, has shown positive results in a phase 3 trial for children and adolescents with type 2 diabetes, meeting all primary and key secondary endpoints [4] - The trial demonstrated significant improvements in A1C and BMI compared to placebo [4] Technological Advancements - Eli Lilly has introduced TuneLab, which consists of AI models and proprietary data, representing an investment of over $1 billion [5] - The company aims to leverage AI to enhance drug development processes for biotech companies [5]

We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Even though Eli Lilly and Company (NYSE:LLY)’s shares have lost 6.9% year-to-date, Cramer continues to be a believer in the stock. He believes that the firm is establishing a strong manufacturing presence in the US and outlined that his “original prediction” of the firm becoming the first $1 trillion non-tech company could b ...

Core Insights - Eli Lilly and Company has officially opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, aimed at supporting early-stage biotechnology companies by providing lab space and collaboration opportunities with Lilly scientists [1][2]. Group 1: Facility and Operations - The new facility spans 82,514 square feet and can accommodate up to 15 life sciences companies, employing over 250 individuals from LGL-based companies [2]. - The San Diego site is part of a broader network of innovation hubs, with existing locations in South San Francisco and Boston, and a newly opened site in Beijing [2][4]. Group 2: Strategic Goals and Collaboration - Lilly's commitment to the biotech ecosystem is highlighted by its approach to support companies at every stage of development, emphasizing collaboration with academia, biotech, and large pharmaceutical companies [2][3]. - The Gateway Labs model provides startups with access to wet lab facilities, tailored scientific engagement, and strategic guidance to navigate drug discovery complexities [2][3]. Group 3: Financial Impact and Growth - Since the inception of the first Gateway Labs site in 2019, companies within the program have raised over $2 billion in capital, facilitating the development of more than 50 therapeutics and platforms [2][5]. - The model has demonstrated sustained growth through a high-touch partnership approach, focusing on helping biotech companies avoid common pitfalls [3].